Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-Hib-IPV vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-Hib-IPV is a pentavalent combination vaccine designed to provide active immunization against five major pediatric infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine typically consists of purified diphtheria and tetanus toxoids, acellular pertussis antigens (including pertussis toxoid, filamentous hemagglutinin, and pertactin), inactivated poliovirus types 1, 2, and 3, and the Hib capsular polysaccharide (polyribosylribitol phosphate) conjugated to a carrier protein. In the context of Novartis Vaccines' clinical development program for its meningococcal conjugate portfolio (specifically the MenACWY-CRM vaccine, Menveo), DTaP-Hib-IPV was utilized as a concomitant vaccine in Phase 2 and Phase 3 trials to evaluate the safety and immunogenicity of the meningococcal vaccine when integrated into standard childhood immunization schedules.
- Brand names
- Infanrix IPV+HibPentacel
- Other names
- DTaP-Hib-IPVDTPa-Hib-IPVPentavalent vaccine (DTaP-Hib-IPV)
02
Targets
BCR (Immunoglobulin G B Cell Receptor)FHA (Filamentous hemagglutinin)WPV3 (Poliovirus type 3 capsid protein)PRN (Pertactin)γδ TCR (T-cell receptor)TT (Tetanus toxoid)PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on DTaP-Hib-IPV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-Hib-IPV vaccine.